The presence of a graft-versus-tumor effect has been well established in leukemia but not in multiple myeloma. A 40-year-old patient with myeloma refractory to standard chemotherapy and autologous transplantation received a matched unrelated T-cell-depleted transplant after conditioning with fractionated total-body irradiation, thiotepa, and cyclophosphamide. This procedure resulted in a transient and incomplete response with evidence of rapidly progressive disease within 2.5 months posttransplantation. The patient then received a small number of donor peripheral blood (PB) mononuclear cells (CD3 cells 1.2 x 10(6)/kg) without any further cytotoxic therapy. A complete remission was attained, lasting now for more than 14 months. The procedure was associated with severe acute and subsequently limited chronic graft- versus-host disease (GVHD). This report provides the first direct evidence of a graft-versus-myeloma effect after allogenic transplantation.
ARTICLES| February 1, 1996
Graft-versus-myeloma effect: proof of principle
Blood (1996) 87 (3): 1196-1198.
- Share Icon Share
- Tools Icon Tools
- Search Site
- PDF LinkPDF
G Tricot, DH Vesole, S Jagannath, J Hilton, N Munshi, B Barlogie; Graft-versus-myeloma effect: proof of principle. Blood 1996; 87 (3): 1196–1198. doi: https://doi.org/10.1182/blood.V87.3.1196.bloodjournal8731196
Download citation file: